A Phase 1 interventional study of LY-CovMab in Covid19, sponsored by Luye Pharma Group Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-07-22.
Sponsored by Luye Pharma Group Ltd. · Phase 1, Interventional, and Treatment
A single center, randomized, doubled-blind, placebo-control and single ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of LY-CovMab Injection in Chinese healthy subjects.
A single center, randomized, doubled-blind, placebo-control and single ascending dose phase I study:
Primary objective: to evaluate the safety and tolerability of a single dose of LY-CovMab Injection in Chinese healthy subjects.
Secondary objective: to evaluate the pharmacokinetics (PK) and immunogenicity of a single dose of LY-CovMab injection in Chinese healthy subjects.
Luye Pharma Group Ltd. is the lead sponsor of 72 studies on the registry; 15 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
A signed informed consent form (ICF) from the patient or their legally authorized representative.
Healthy males or females, ages ≥18 to ≤45 years. Male subjects with weight ≥50 kg, or female subjects with weight ≥45 kg, and body mass index (BMI) 19.0≤BMI≤26.0 kg/m2.
No abnormality, or no clinically significant abnormality in vital signs, physical examination, laboratory tests, and 12-lead ECG in Chinese healthy subjects during the screening period.
Female patients of childbearing potential (defined as female subjects who do not receive any operative sterilization or who had been through menopause for less than 1 year) must have a negative result for pregnancy test at screening. Male and female subjects with childbearing potential must agree to adopt effective contraceptive methods at least from 2 weeks prior to screening to 6 months after administration of the investigational drug.
Exclusion Criteria:
Those who have had surgery within 8 weeks prior to screening or who have surgery planned during the trial, and the investigator believes that such surgery may bring potential risks to the subjects.
Prior to administration of the investigational drug, use of the following drugs or therapies:
i. any prescription drug within 28 days. ii. any over-the-counter drug, including health care products within 7 days.
Prior history or current evidence of serious disease or chronic disease of the respiratory system, circulatory system, digestive system, urinary system, reproductive system, nervous system, immune system, hematology, psychiatry, and dermatology, etc, or any disease that may interfere with the trial results.
Subjects with coronavirus disease 2019 (COVID-19) or recovered from it or subjects positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid or serum SARS-CoV-2 specific antibodies.
Subjects who are with known history of allergies to any ingredient of the investigational drug, or similar drugs, or subjects with allergic constitution (previously sensitive to ≥ 2 foods or drugs).
Subjects with any positive test of hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, treponema pallidum antibody, or human immunodeficiency virus (HIV) antibody.
Subjects with alcohol abuse or tobacco abuse, or alcohol blood test results exceeding the upper limit of the normal range. Alcohol abuse is defined as: alcohol consumption of more than 14 U (1 U = 350 mL of beer, or 45 mL of liquor, or 150 mL of wine) per week within 3 months prior to screening. Tobacco abuse is defined as: smoking ≥5 cigarettes per day on average within 3 months prior to screening.
Female subjects (including partners) who plan to be pregnant within one year upon screening, or pregnant or breast-feeding female subjects.
Subjects with a history of drug addiction or drug abuse, or with positive urine screen test results for drug.
Subjects donating whole blood or blood components, or with massive hemorrhage (>400 mL), within 3 months prior to screening.
Prior vaccination with SARS-CoV-2 vaccine or participation in a SARS-CoV-2 neutralizing antibody clinical trial. Participation in any other clinical study with pharmacological intervention within 3 months prior to screening, or the drug is still within the elimination period (5 half-lives) prior to screening, whichever is longer. Vaccination within 12 weeks prior to screening, or planned vaccination during the study and within 12 weeks after the end of the study.
Subjects with a history of fainting at the sight of blood or puncture. Subjects who are not suitable to participate in the clinical trial as considered by the investigator or cannot complete the study for any other reasons.
LY-CovMab is diluted with 0.9% sodium chloride to a total volume of 250 mL for IV infusion
Drug: LY-CovMab
LY-CovMab is diluted with 0.9% sodium chloride to a total volume of 250 mL for IV infusion
Drug: LY-CovMab
LY-CovMab is diluted with 0.9% sodium chloride to a total volume of 250 mL for IV infusion
Drug: LY-CovMab
LY-CovMab is diluted with 0.9% sodium chloride to a total volume of 250 mL for IV infusion
Drug: LY-CovMab
LY-CovMab is diluted with 0.9% sodium chloride to a total volume of 250 mL for IV infusion
Drug: LY-CovMab
Placebo is diluted with 0.9% sodium chloride to a total volume of 250 mL for IV infusion
Drug: LY-CovMab
single IV infusion
Treatment-emergent Changes in Body Temperature
Grade of treatment-emergent changes in body temperature by Common Terminology Criteria for Adverse Event (CTCAE) scale version 5.0. The scale ranges from Grade 1 (Mild) to Grade 5 (Most Severe).
Time frame: up to 99 days
Treatment-emergent Changes in Respiratory Rate
Grade of treatment-emergent changes in respiratory rate by Common Terminology Criteria for Adverse Event (CTCAE) scale version 5.0. The scale ranges from Grade 1 (Mild) to Grade 5 (Most Severe).
Time frame: up to 99 days
Treatment-emergent Changes in Pulse Rate
Grade of treatment-emergent changes in pulse rate by Common Terminology Criteria for Adverse Event (CTCAE) scale version 5.0. The scale ranges from Grade 1 (Mild) to Grade 5 (Most Severe).
Time frame: up to 99 days
Treatment-emergent Changes in Blood Pressure
Grade of treatment-emergent changes in blood pressure by Common Terminology Criteria for Adverse Event (CTCAE) scale version 5.0. The scale ranges from Grade 1 (Mild) to Grade 5 (Most Severe).
Time frame: up to 99 days
Safety Laboratory Value (Haematology)
Haematology laboratory value by Common Terminology Criteria for Adverse Event (CTCAE) scale version 5.0 (absolute and change from baseline where identified). The scale ranges from Grade 1 (Mild) to Grade 5 (Most Severe).
Time frame: D-1, D4, D8, D15, D29, D50, D99
Safety Laboratory Value (blood chemistry)
Serum Chemistry laboratory value by Common Terminology Criteria for Adverse Event (CTCAE) scale version 5.0 (absolute and change from baseline where identified). The scale ranges from Grade 1 (Mild) to Grade 5 (Most Severe).
Time frame: D-1, D4, D8, D15, D29, D50, D99
Frequency and Grade of Adverse Events
Time frame: up to 99 days
Assess safety profile of LY-CovMab
12 lead electrocardiogram (ECG) heart rate
Time frame: D-1, D4, D8, D15, D29, D50, D99
Assess safety profile of LY-CovMab
12 lead electrocardiogram (ECG) PR interval
Time frame: D-1, D4, D8, D15, D29, D50, D99
Assess safety profile of LY-CovMab
12 lead electrocardiogram (ECG) QTc interval
Time frame: D-1, D4, D8, D15, D29, D50, D99
Assess safety profile of LY-CovMab
12 lead electrocardiogram (ECG) QRS interval
Time frame: D-1, D4, D8, D15, D29, D50, D99
Assess Pharmacokinetic parameters of LY-CovMab
Maximum observed concentration (Cmax)
Time frame: up to 99 days
Assess Pharmacokinetic parameters of LY-CovMab
Time to maximum observed concentration (Tmax)
Time frame: up to 99 days
Assess Pharmacokinetic parameters of LY-CovMab
Area under the concentration-time curve from time 0 to the time of the last quantifiable concentration (AUC0 last)
Time frame: up to 99 days
Assess Pharmacokinetic parameters of LY-CovMab
Percentage of the extrapolated area under the concentration-time curve (AUC_%Extrap)
Time frame: up to 99 days
Assess Pharmacokinetic parameters of LY-CovMab
Area under the concentration-time curve from time 0 to infinity (AUC0-inf),
Time frame: up to 99 days
Assess Pharmacokinetic parameters of LY-CovMab
Clearance (CL)
Time frame: up to 99 days
Assess Pharmacokinetic parameters of LY-CovMab
Half-life (t1/2)
Time frame: up to 99 days
Assess Pharmacokinetic parameters of LY-CovMab
Volume of distribution (Vd)
Time frame: up to 99 days
Assess the immunogenicity of LY-CovMab
Incidence of anti-drug antibody (ADA)
Time frame: D1, D15, D29, D43, D57, D71, D99
Assess the immunogenicity of LY-CovMab
Incidence of neutralizing antibody (Nab)
Time frame: D1, D15, D29, D43, D57, D71, D99
Plan to share: No
This study is status unknown, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Luye Pharma Group Ltd.